- Home
- LUNG vs ATAI Comparison
LUNG vs ATAI Comparison
Compare LUNG & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- ATAI
- Stock Information
- Founded
- LUNG 1995
- ATAI 2018
- Country
- LUNG United States
- ATAI Germany
- Employees
- LUNG N/A
- ATAI N/A
- Industry
- LUNG Industrial Specialties
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- ATAI Health Care
- Exchange
- LUNG Nasdaq
- ATAI Nasdaq
- Market Cap
- LUNG 299.3M
- ATAI 271.6M
- IPO Year
- LUNG 2020
- ATAI 2021
- Fundamental
- Price
- LUNG $7.87
- ATAI $1.35
- Analyst Decision
- LUNG Strong Buy
- ATAI Strong Buy
- Analyst Count
- LUNG 7
- ATAI 4
- Target Price
- LUNG $12.64
- ATAI $9.00
- AVG Volume (30 Days)
- LUNG 464.2K
- ATAI 2.1M
- Earning Date
- LUNG 04-30-2025
- ATAI 03-17-2025
- Dividend Yield
- LUNG N/A
- ATAI N/A
- EPS Growth
- LUNG N/A
- ATAI N/A
- EPS
- LUNG N/A
- ATAI N/A
- Revenue
- LUNG $83,789,000.00
- ATAI $308,000.00
- Revenue This Year
- LUNG $17.96
- ATAI N/A
- Revenue Next Year
- LUNG $18.35
- ATAI $20.00
- P/E Ratio
- LUNG N/A
- ATAI N/A
- Revenue Growth
- LUNG 22.01
- ATAI N/A
- 52 Week Low
- LUNG $5.46
- ATAI $0.78
- 52 Week High
- LUNG $10.01
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- LUNG 52.84
- ATAI 39.19
- Support Level
- LUNG $7.65
- ATAI $1.34
- Resistance Level
- LUNG $8.12
- ATAI $1.52
- Average True Range (ATR)
- LUNG 0.56
- ATAI 0.11
- MACD
- LUNG -0.06
- ATAI -0.02
- Stochastic Oscillator
- LUNG 46.86
- ATAI 16.87
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.